Katelyn Dvorsky, PA
Payments from drug & device makers
Across 123 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$581
- E.r. Squibb & Sons, L.L.C.$345
- Johnson & Johnson$307
- Sanofi$291
- Regeneron Healthcare Solutions, Inc.$268
- Amgen$198
- plus $736 from 13 others
What the payments were for
- Food & beverage$2,54093%
- Education$1867%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $581 |
| E.r. Squibb & Sons, L.L.C. | 16 | $345 |
| Johnson & Johnson | 10 | $307 |
| Sanofi | 11 | $291 |
| Regeneron Healthcare Solutions, Inc. | 10 | $268 |
| Amgen | 8 | $198 |
| Pfizer | 9 | $184 |
| UCB, Inc. | 7 | $134 |
| Novartis | 3 | $87 |
| Sun Pharmaceutical Industries Inc. | 2 | $70 |
| Galderma Laboratories, L.p. | 3 | $57 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Incyte Corporation | 2 | $39 |
| Kerecis Limited | 1 | $29 |
| LEO Pharma Inc. | 1 | $28 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$2,726 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 20 | $81,971 |
| Clobetasol Propionate | 129 | $4,348 |
| Fluorouracil | 34 | $2,488 |
| Tretinoin | 13 | $898 |
| Doxycycline Hyclate | 29 | $882 |
| Ketoconazole | 60 | $756 |
| Clindamycin Phosphate | 15 | $457 |
| Econazole Nitrate | 11 | $379 |
| Triamcinolone Acetonide | 43 | $340 |
| Cephalexin | 21 | $320 |
| Desonide | 12 | $283 |
| Mupirocin | 24 | $224 |
| Oxybutynin Chloride | 14 | $165 |
| Prednisone | 14 | $112 |
Paid to pharmacies, not to this prescriber.
Other medical in Waco
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.